Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
62,139,394
-
Share change
-
+938,554
-
Total reported value
-
$1,874,756,231
-
Put/Call ratio
-
48%
-
Price per share
-
$30.17
-
Number of holders
-
143
-
Value change
-
+$24,663,304
-
Number of buys
-
70
-
Number of sells
-
67
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q3 2020
As of 30 Sep 2020,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
143 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,139,394 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., HILLHOUSE CAPITAL ADVISORS, LTD., VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, JENNISON ASSOCIATES LLC, FARALLON CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, and VICTORY CAPITAL MANAGEMENT INC.
This page lists
143
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.